Liquidia Corp
LQDA13.100USD
+0.270+2.10%
Close 06/27, 16:00（ET）Quotes delayed by 15 min
1.12BMarket Cap
LossP/E TTM
More Details of Liquidia Corp Company
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Company Info
Ticker SymbolLQDA
Company nameLiquidia Corp
IPO dateJul 26, 2018
Founded at2020
CEODr. Roger A. Jeffs, Ph.D.
Number of employees157
Security typeOrdinary Share
Fiscal year-endJul 26
Address419 Davis Drive
CityMORRISVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code27560
Phone19193284400
Websitehttps://www.liquidia.com/
Ticker SymbolLQDA
IPO dateJul 26, 2018
Founded at2020
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.13M
+1.85%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
372.72K
+2.59%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
266.92K
+3.92%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
216.08K
+4.00%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
161.93K
+5.42%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
146.34K
+10.17%
Mr. Damian Degoa
Mr. Damian Degoa
Independent Director
Independent Director
66.11K
+38.55%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
50.40K
+57.49%
Dr. Joanna C. Horobin
Dr. Joanna C. Horobin
Independent Director
Independent Director
18.40K
--
Ms. Katherine (Katie) Rielly-Gauvin
Ms. Katherine (Katie) Rielly-Gauvin
Independent Director
Independent Director
18.40K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.13M
+1.85%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
372.72K
+2.59%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
266.92K
+3.92%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
216.08K
+4.00%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
161.93K
+5.42%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
146.34K
+10.17%
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
14.00M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Caligan Partners, LP
9.50%
Manning (Paul B.)
7.21%
BlackRock Institutional Trust Company, N.A.
4.91%
Farallon Capital Management, L.L.C.
4.67%
The Vanguard Group, Inc.
4.04%
Other
69.67%
Shareholders
Shareholders
Proportion
Caligan Partners, LP
9.50%
Manning (Paul B.)
7.21%
BlackRock Institutional Trust Company, N.A.
4.91%
Farallon Capital Management, L.L.C.
4.67%
The Vanguard Group, Inc.
4.04%
Other
69.67%
Shareholder Types
Shareholders
Proportion
Hedge Fund
30.69%
Investment Advisor/Hedge Fund
15.97%
Investment Advisor
12.67%
Individual Investor
11.55%
Research Firm
3.48%
Corporation
2.69%
Private Equity
1.78%
Bank and Trust
0.26%
Pension Fund
0.21%
Other
20.70%
Institutional Shareholding
Updated: Tue, Mar 4
Updated: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
344
64.23M
75.45%
-9.89M
2024Q4
344
63.62M
75.17%
-10.09M
2024Q3
335
73.31M
89.39%
+16.42M
2024Q2
318
66.67M
87.88%
+4.98M
2024Q1
302
59.34M
79.61%
+7.64M
2023Q4
256
48.15M
70.41%
+4.56M
2023Q3
236
40.52M
62.49%
-5.87M
2023Q2
223
41.12M
63.56%
-6.16M
2023Q1
214
42.01M
65.00%
-5.41M
2022Q4
210
41.20M
63.89%
-7.92M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Caligan Partners, LP
8.12M
9.52%
--
--
Dec 31, 2024
Manning (Paul B.)
6.15M
7.21%
+316.72K
+5.43%
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
4.18M
4.9%
+416.76K
+11.07%
Dec 31, 2024
Farallon Capital Management, L.L.C.
3.29M
3.86%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
3.55M
4.16%
+115.37K
+3.36%
Dec 31, 2024
Findell Capital Management LLC
3.08M
3.61%
-113.54K
-3.56%
Dec 31, 2024
Opaleye Management Inc.
1.70M
1.99%
--
--
Dec 31, 2024
Jeffs (Roger A)
2.19M
2.56%
+206.98K
+10.46%
Jan 14, 2025
Legend Aggregator LP
1.86M
2.18%
-5.32M
-74.10%
Dec 31, 2024
State Street Global Advisors (US)
1.81M
2.12%
-363.63K
-16.72%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
Invesco Pharmaceuticals ETF
2.76%
Invesco Dorsey Wright Healthcare Momentum ETF
1.97%
SPDR S&P Pharmaceuticals ETF
1.71%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.11%
ALPS Medical Breakthroughs ETF
1.08%
Virtus LifeSci Biotech Clinical Trials ETF
1.01%
iShares U.S. Pharmaceuticals ETF
0.3%
First Trust Small Cap Growth AlphaDEX Fund
0.27%
SPDR S&P Kensho New Economies Composite ETF
0.22%
iShares Micro-Cap ETF
0.21%
View more
Invesco Pharmaceuticals ETF
Proportion2.76%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.97%
SPDR S&P Pharmaceuticals ETF
Proportion1.71%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.11%
ALPS Medical Breakthroughs ETF
Proportion1.08%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.01%
iShares U.S. Pharmaceuticals ETF
Proportion0.3%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.27%
SPDR S&P Kensho New Economies Composite ETF
Proportion0.22%
iShares Micro-Cap ETF
Proportion0.21%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
